FarmaMondo Group Welcomes Natalie Douglas to Its Board as Director
FarmaMondo Group, an international leader in the pharmaceutical industry, has announced the appointment of Natalie Douglas as an Independent Board Director. Renowned for her remarkable contributions to managed access and commercialization within pharmaceuticals, Douglas's expertise is set to guide FarmaMondo as it seeks to broaden its reach in the U.S. market.
Based in both Princeton, New Jersey, and Chiasso, Switzerland, FarmaMondo operates in over 50 emerging markets, partnering with pharmaceutical and biotech companies to deliver innovative medications. Douglas is celebrated for establishing a pioneering model for managed drug access, a framework that has become essential for facilitating patient access to critical therapies worldwide.
Before joining FarmaMondo, Douglas made significant strides in her previous role as head of IDIS, a specialty pharmaceutical organization. There, she transformed the company into a leading provider of managed access programs, facilitating over 200 global access initiatives on behalf of 40 pharmaceutical firms dealing in treatments for severe and rare diseases. This achievement culminated in IDIS's acquisition by Clinigen Group, underscoring the impact of her transformative work.
Yaron Spigel, the CEO of FarmaMondo, expressed enthusiasm about Douglas's appointment, referring to her as a key figure in the realm of global patient access. He emphasized that her leadership will be crucial as the company strengthens partnerships with U.S. pharmaceutical organizations. Spigel believes that Douglas's experience dovetails perfectly with FarmaMondo's vision to comprehensively meet the needs of patients across the globe.
"It’s a privilege to lend my expertise in global access to FarmaMondo and assist in expanding its U.S. market presence," said Douglas. She expressed admiration for the company's innovative approach in fostering relationships between pharma partners and healthcare facilities, particularly in underserved regions. "FarmaMondo’s commitment aligns with my passion for ensuring that patients, regardless of their geographical barriers, have access to life-changing treatments.
FarmaMondo is currently at a pivotal juncture in its growth strategy, rapidly expanding its operations and reinforcing its presence in the highly competitive U.S. market. The organization currently boasts 14 regional affiliates and leverages a diverse portfolio that includes oncology, specialty and rare disease therapies encompassing over 50 products in multiple nations. Douglas's unparalleled leadership in fostering expanded access programs positions her as an invaluable board member to enhance FarmaMondo's efforts to serve more patients effectively.
As FarmaMondo continues to evolve, its goal remains consistent: to ensure that essential medicines reach those in need, particularly in the less accessible markets around the world. With Natalie Douglas on board, the company's mission of facilitating patient access to healthcare is likely to advance significantly.
About FarmaMondo Group
FarmaMondo Group is dedicated to bridging the gap between pharmaceutical manufacturers and the emerging markets. By offering integrated market solutions from early access to commercialization, FarmaMondo aims to ensure the availability of life-altering medicines to patients who require them across more than fifty countries. The organization is committed to social responsibility, ensuring that no patient is left behind in critical times of need.
For further inquiries, please contact:
Ivy Cohen
Corporate Communications
+1 (212) 399-0026
[email protected]
Based in both Princeton, New Jersey, and Chiasso, Switzerland, FarmaMondo operates in over 50 emerging markets, partnering with pharmaceutical and biotech companies to deliver innovative medications. Douglas is celebrated for establishing a pioneering model for managed drug access, a framework that has become essential for facilitating patient access to critical therapies worldwide.
Before joining FarmaMondo, Douglas made significant strides in her previous role as head of IDIS, a specialty pharmaceutical organization. There, she transformed the company into a leading provider of managed access programs, facilitating over 200 global access initiatives on behalf of 40 pharmaceutical firms dealing in treatments for severe and rare diseases. This achievement culminated in IDIS's acquisition by Clinigen Group, underscoring the impact of her transformative work.
Yaron Spigel, the CEO of FarmaMondo, expressed enthusiasm about Douglas's appointment, referring to her as a key figure in the realm of global patient access. He emphasized that her leadership will be crucial as the company strengthens partnerships with U.S. pharmaceutical organizations. Spigel believes that Douglas's experience dovetails perfectly with FarmaMondo's vision to comprehensively meet the needs of patients across the globe.
"It’s a privilege to lend my expertise in global access to FarmaMondo and assist in expanding its U.S. market presence," said Douglas. She expressed admiration for the company's innovative approach in fostering relationships between pharma partners and healthcare facilities, particularly in underserved regions. "FarmaMondo’s commitment aligns with my passion for ensuring that patients, regardless of their geographical barriers, have access to life-changing treatments.
FarmaMondo is currently at a pivotal juncture in its growth strategy, rapidly expanding its operations and reinforcing its presence in the highly competitive U.S. market. The organization currently boasts 14 regional affiliates and leverages a diverse portfolio that includes oncology, specialty and rare disease therapies encompassing over 50 products in multiple nations. Douglas's unparalleled leadership in fostering expanded access programs positions her as an invaluable board member to enhance FarmaMondo's efforts to serve more patients effectively.
As FarmaMondo continues to evolve, its goal remains consistent: to ensure that essential medicines reach those in need, particularly in the less accessible markets around the world. With Natalie Douglas on board, the company's mission of facilitating patient access to healthcare is likely to advance significantly.
- ---
About FarmaMondo Group
FarmaMondo Group is dedicated to bridging the gap between pharmaceutical manufacturers and the emerging markets. By offering integrated market solutions from early access to commercialization, FarmaMondo aims to ensure the availability of life-altering medicines to patients who require them across more than fifty countries. The organization is committed to social responsibility, ensuring that no patient is left behind in critical times of need.
For further inquiries, please contact:
Ivy Cohen
Corporate Communications
+1 (212) 399-0026
[email protected]
Topics Health）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.